Neutral CB1 Antagonists Can Help Identify Ongoing Endocannabinoid Tone

A response to a neutral CB1 antagonist can provide different evidence from a response to an inverse agonist. The distinction matters when an experiment asks whether endogenous cannabinoids were already activating the receptor.

The two blockers do different things

Kunos’s 2020 review explains that an inverse agonist can reduce constitutive receptor activity even without occupancy by an endogenous ligand. Its effect therefore supports receptor involvement without, on its own, proving ongoing endocannabinoid activation.

A neutral antagonist blocks agonist action without the same inverse-agonist action. In the absence of a previously administered agonist, a response to that blockade more strongly supports preexisting activation by an endogenous ligand.

An alcohol experiment used this distinction

The review describes AM4113, a neutral CB1 antagonist, reducing binge-like alcohol drinking in male mice. It also attenuated alcohol-induced dopamine release measured by microdialysis in the nucleus accumbens.

Those findings supported a contribution from endogenous cannabinoid signaling to the measured behaviors and transmitter response. The conclusion concerns the tested model and does not identify every relevant ligand, cell population or anatomical pathway.

Mechanistic evidence is separate from clinical suitability

Neutral antagonism is useful for interpreting an experiment, but it does not guarantee that a compound has no adverse effects or will be an effective human treatment. Those questions require their own evidence.

When reviewing a claim about endocannabinoid tone, ask which kind of blocker was used and whether an exogenous agonist was present. Treating all receptor blockers as equivalent can turn evidence of receptor activity into an overly specific claim about what activated it.

Related reading: Neutral CB1 Antagonism Did Not Guarantee Absence of Behavioral Side Effects.

Research cited

Kunos G. Interactions Between Alcohol and the Endocannabinoid System (2020). This analysis draws on the review’s discussion of the cited experiments.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Four-Day Session Washout Was Not Four Days of Cannabis Abstinence

The interval between experimental sessions should not be mistaken for verified cannabis abstinence. In a heavy-user study, participants could continue their usual cannabis routine despite a minimum four-day interval between treatments. The instructions defined the exposure history Ramaekers and colleagues allowed usual cannabis smoking during the study period. Participants were…

Spread the love

Read Article: A Four-Day Session Washout Was Not Four Days of Cannabis Abstinence

Booster Alcohol Doses Changed What a Cannabis Cross-Tolerance Study Tested

Maintaining alcohol concentrations with repeated booster doses tests a different exposure pattern from a single drink followed by falling concentrations. That difference mattered in a study of heavy cannabis users. The protocol aimed to sustain exposure Ramaekers and colleagues targeted steady alcohol concentrations across several hours, using booster doses as…

Spread the love

Read Article: Booster Alcohol Doses Changed What a Cannabis Cross-Tolerance Study Tested

The Primate THC Study Did Not Directly Measure Drug Metabolism as a Tolerance Mechanism

A behavioral pattern consistent with receptor adaptation does not independently rule out pharmacokinetic contributions. A primate study explicitly states that drug metabolism and disposition were not assessed. The behavioral comparison supported a receptor hypothesis McMahon found different degrees of tolerance and cross-tolerance among THC and synthetic cannabinoid agonists. The pattern…

Spread the love

Read Article: The Primate THC Study Did Not Directly Measure Drug Metabolism as a Tolerance Mechanism

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us